TY - JOUR
T1 - Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women
T2 - The women’s health initiative
AU - Pan, Kathy
AU - Nelson, Rebecca A.
AU - Wactawski-Wende, Jean
AU - Lee, Delphine J.
AU - Manson, Jo Ann E.
AU - Aragaki, Aaron K.
AU - Mortimer, Joanne E.
AU - Phillips, Lawrence S.
AU - Rohan, Thomas
AU - Ho, Gloria Y.F.
AU - Saquib, Nazmus
AU - Shadyab, Aladdin H.
AU - Nassir, Rami
AU - Rhee, Jinnie J.
AU - Hurria, Arti
AU - Chlebowski, Rowan T.
N1 - Publisher Copyright:
© The Author(s) 2019. Published by Oxford University Press. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: Insulin resistance has been proposed as a mediator of the increased cancer incidence and mortality associated with obesity. However, prior studies included limited cancer deaths and had inconsistent findings. Therefore, we evaluated insulin resistance and cancer-specific and all-cause mortality in postmenopausal women participating in the Women’s Health Initiative (WHI). Methods: Eligible were a subsample of 22 837 WHI participants aged 50–79 years enrolled at 40 US clinical centers from 1993 to 1998 who had baseline fasting glucose and insulin levels. Baseline insulin resistance was measured by the homeostasis model assessment of insulin resistance (HOMA-IR). Cancers were verified by central medical record review and deaths verified by medical record and death certificate review enhanced by National Death Index queries. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality. All statistical tests were two-sided. Results: During a median of 18.9 years of follow-up, 1820 cancer deaths and 7415 total deaths occurred. Higher HOMA-IR quartile was associated with higher cancer-specific mortality (Q4 vs Q1, HR ¼ 1.26, 95% CI ¼ 1.09 to 1.47; Ptrend ¼ .003) and all-cause mortality (Q4 vs Q1, HR ¼ 1.63, 95% CI ¼ 1.51 to 1.76; Ptrend < .001). A sensitivity analysis for diabetes status did not change findings. Among women with body mass index less than 25 kg/m2, higher HOMA-IR quartile was associated with higher cancer mortality (Fine and Gray, P ¼ .004). Conclusions: High insulin resistance, as measured by HOMA-IR, identifies postmenopausal women at higher risk for cancer-specific and all-cause mortality who could potentially benefit from early intervention.
AB - Background: Insulin resistance has been proposed as a mediator of the increased cancer incidence and mortality associated with obesity. However, prior studies included limited cancer deaths and had inconsistent findings. Therefore, we evaluated insulin resistance and cancer-specific and all-cause mortality in postmenopausal women participating in the Women’s Health Initiative (WHI). Methods: Eligible were a subsample of 22 837 WHI participants aged 50–79 years enrolled at 40 US clinical centers from 1993 to 1998 who had baseline fasting glucose and insulin levels. Baseline insulin resistance was measured by the homeostasis model assessment of insulin resistance (HOMA-IR). Cancers were verified by central medical record review and deaths verified by medical record and death certificate review enhanced by National Death Index queries. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality. All statistical tests were two-sided. Results: During a median of 18.9 years of follow-up, 1820 cancer deaths and 7415 total deaths occurred. Higher HOMA-IR quartile was associated with higher cancer-specific mortality (Q4 vs Q1, HR ¼ 1.26, 95% CI ¼ 1.09 to 1.47; Ptrend ¼ .003) and all-cause mortality (Q4 vs Q1, HR ¼ 1.63, 95% CI ¼ 1.51 to 1.76; Ptrend < .001). A sensitivity analysis for diabetes status did not change findings. Among women with body mass index less than 25 kg/m2, higher HOMA-IR quartile was associated with higher cancer mortality (Fine and Gray, P ¼ .004). Conclusions: High insulin resistance, as measured by HOMA-IR, identifies postmenopausal women at higher risk for cancer-specific and all-cause mortality who could potentially benefit from early intervention.
UR - http://www.scopus.com/inward/record.url?scp=85079341377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079341377&partnerID=8YFLogxK
U2 - 10.1093/JNCI/DJZ069
DO - 10.1093/JNCI/DJZ069
M3 - Article
C2 - 31184362
AN - SCOPUS:85079341377
SN - 0027-8874
VL - 112
SP - 170
EP - 178
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -